Dr CHEW CHANG CHUAN

Dynamic Nephrologist and Medical Lecturer at University Malaya Medical Centre, skilled in glomerular diseases, and chronic kidney disease care. Proven ability to manage complex cases, including lupus nephritis and diabetic nephropathy. Committed to patient education and fostering a collaborative healthcare environment, enhancing treatment outcomes through effective communication and expertise. A true advocate in kidney transplant.

Experienced with designing and delivering educational content that engages and inspires students. Utilizes innovative teaching methods to enhance learning outcomes and foster positive classroom environment. Strong understanding of curriculum development and student assessment techniques.

1) APSDA-MSN Congress 2019

- Published case report entitled ' Persistent Left Superior Vena cava syndrome '

- Published case report entitled ' Challenges in Managing a Case of Healthcare associated Infective Endocarditis ( HaIE) complicated with Early Septic Embolisation

2) Case report during the BRTMA- Malaysia International Congress on tropical Medicine 2019 titled: An Unusual Presentation of Invasive Enterococcus Fecalis Infection

3) “Anugerah Perkhidmatan Cemerlang “ Ministry of Health Malaysia – 2016, 2017

4) Mini-oral presenter at 2023 ANZSN Annual Scientific Meeting - AN ANALYSIS OF ARTERIO-VENOUS FISTULA AND NT-PRO BNP AFTER KIDNEY TRANSPLANTATION.

5) Oral Presentation and Young Investigator Award consolation prize winner: "The Utility of Urine Soluble CD163 in Predicting Disease Activity of Lupus Nephritis, A Single Centre Pilot Study." at the 38th Annual Congress of Malaysian Society of Nephrology (MSN) 2024.

6) Goh, En Thong; Gan, Chye Chung; Lim, Soo Kun; Wong, Chew Ming; Lee, Yee Wan; Chew, Chang Chuan; Jalalonmuhali, Maisarah (2022). Metabolic Changes In Living Kidney Donors After Donation In University Malaya Medical Centre, TRANSPLANTATION PROCEEDINGS. 54(2), 242-247. doi:10.1016/j.transproceed.2022.01.006

1) Malaysian Society of Nephrology ( MSN)

2) International Society of Nephrology ( ISN)

3) American Society of Nephrology ( ASN)

4) International Society of Peritoneal Dialysis ( ISPD)

5) MRCP(UK) - Edinburgh

6) Malaysian Medical Association (MMA)

1. 2021 - 2026, NOVO NORDISK PHARMA (MALAYSIA) SDN. BHD.

ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation (2021-10-26 - 2026-02-27) ( Co-Researcher)

2. 2022 - 2025, Eledon Pharmaceuticals, Inc.

A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease ( Co-Researcher)

3. 2023 - 2025, DEPARTMENT OF MEDICINE (DOM) UMMC

URINE SOLUBLE CD 163 AS A NOVEL NON-INVASIVE BIOMARKER AND HISTO-PATHOLOGICAL CHARACTERIZATION OF MACROPHAGES IN LUPUS NEPHRITIS, A CLINICAL OUTCOME STUDY ( Co-Inventor)

4. 2023 - 2026, KEZAR LIFE SCIENCES, INC

A PHASE 2B, RANDOMIZED, CONTROLLED DOUBLE-BLIND,MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF ZETOMIPZOMIB (KZR-616) 30 MG OR 60 MG WITH PLACEBO IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS ( Co-Researcher)

5. 2021 - 2023, ASTRAZENECA AB (PUBL)

D7551C00001 (PXL: 248068) / FLAIR - A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease (2021-04-01 - 2023-12-31) ( Co-Researcher)